HighPoint Advisor Group’s Bio-Rad Laboratories Class A BIO Stock Holding History

HighPoint Advisor Group’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-738	Closed	-$224K	–	690
2025 Q4	$224K	Sell	738 -11	-1%	-$3.43K	﹤0.01%	986
2025 Q3	$210K	Buy	+749	New	+$204K	0.01%	649
2024 Q4	–	Sell	-613	Closed	-$226K	–	703
2024 Q3	$226K	Buy	+613	New	+$195K	0.01%	580
2024 Q1	–	Sell	-609	Closed	-$208K	–	652
2023 Q4	$208K	Buy	+609	New	+$191K	0.01%	581
2022 Q2	$607K	Buy	+1,191	New	+$620K	0.07%	242
2021 Q3	$792K	Sell	1,062 -80	-7%	-$59.9K	0.08%	214
2021 Q2	$736K	Buy	1,142 +149	+15%	+$90.7K	0.07%	227
2021 Q1	$598K	Buy	993 +158	+19%	+$93.6K	0.07%	232
2020 Q4	$531K	Buy	835 +89	+12%	+$50.7K	0.06%	243
2020 Q3	$470K	Buy	746 +91	+14%	+$46.1K	0.09%	197
2020 Q2	$298K	Buy	655 +121	+23%	+$53.4K	0.06%	246
2020 Q1	$231K	Buy	+534	New	+$196K	0.06%	267
2019 Q4	–	Sell	-410	Closed	-$144K	–	380
2019 Q3	$144K	Buy	410 +15	+4%	+$4.89K	0.03%	373
2019 Q2	$123K	Buy	+395	New	+$118K	0.03%	404

Other funds holding BIO

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

HighPoint Advisor Group's BIO Position: Q1 2026 in Review

HighPoint Advisor Group sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2026, closing a stake of 738 shares — an estimated $224K sold.

HighPoint Advisor Group first reported a position in BIO in Q2 2019 and held it in 14 quarters. The position peaked at $792K in Q3 2021. 391 funds tracked by Wall St. Rank hold BIO as of Q1 2026.

HighPoint Advisor Group reported no remaining Bio-Rad Laboratories Class A position as of Q1 2026 after selling out during the quarter.
HighPoint Advisor Group sold 738 Bio-Rad Laboratories Class A shares in Q1 2026, an estimated $224K.
HighPoint Advisor Group first reported a position in Bio-Rad Laboratories Class A in Q2 2019 and held it in 14 quarters.
HighPoint Advisor Group's Bio-Rad Laboratories Class A position peaked at $792K in Q3 2021.
391 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2026.

Based on HighPoint Advisor Group's 13F filing for Q1 2026, filed 14 May 2026.